research article
KP1019, a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients
A review. The promising drug candidate indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) is the second Ru-based anticancer agent to enter clin. trials. In this review, which is an update of a paper from 2006, the exptl. evidence for the proposed mode of action of this coordination compd. is discussed, including transport into the cell via the transferrin cycle and activation by redn. The results of the early clin. development of KP1019 are summarized in which 5 out of 6 evaluated patients experienced disease stabilization with no severe side effects.
Type
research article
Web of Science ID
WOS:000260920000018
Author(s)
Hartinger, Christian G.
Jakupec, Michael A.
Zorbas-Seifried, Stefanie
Egger, Alexander
Berger, Walter
Zorbas, Haralabos
Keppler, Bernhard K.
Date Issued
2008
Published in
Volume
5
Issue
10
Start page
2140
End page
2155
Editorial or Peer reviewed
REVIEWED
Written at
EPFL
EPFL units
Available on Infoscience
July 15, 2009
Use this identifier to reference this record